跳轉至內容
Merck
  • Increased neutrophil extracellular trap-mediated Staphylococcus aureus clearance through inhibition of nuclease activity by clindamycin and immunoglobulin.

Increased neutrophil extracellular trap-mediated Staphylococcus aureus clearance through inhibition of nuclease activity by clindamycin and immunoglobulin.

The Journal of infectious diseases (2014-02-15)
Katrin Schilcher, Federica Andreoni, Satoshi Uchiyama, Taiji Ogawa, Reto A Schuepbach, Annelies S Zinkernagel
摘要

The Gram-positive human pathogen Staphylococcus aureus causes a variety of human diseases such as skin infections, pneumonia, and endocarditis. The micrococcal nuclease Nuc1 is one of the major S. aureus virulence factors and allows the bacterium to avoid neutrophil extracellular trap (NET)-mediated killing. We found that addition of the protein synthesis inhibitor clindamycin to S. aureus LAC cultures decreased nuc1 transcription and subsequently blunted nuclease activity in a molecular beacon-based fluorescence assay. We also observed reduced NET degradation through Nuc1 inhibition translating into increased NET-mediated clearance. Similarly, pooled human immunoglobulin specifically inhibited nuclease activity in a concentration-dependent manner. Inhibition of nuclease activity by clindamycin and immunoglobulin enhanced S. aureus clearance and should be considered in the treatment of S. aureus infections.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
克林霉素 盐酸盐, lincosamide antibiotic
USP
克林霉素 盐酸盐, United States Pharmacopeia (USP) Reference Standard
Supelco
克林霉素 盐酸盐, Pharmaceutical Secondary Standard; Certified Reference Material
克林霉素 盐酸盐, European Pharmacopoeia (EP) Reference Standard